Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data
have Glaucoma
Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
Patients with refractory CME or CME persisting 3 months or more post-operatively
Patients with incomplete IOP, medication logs or VF data within post-operative period
Prior incisional surgery or MIGS
Barnet Dulaney Perkins Eye Centers
Lead sponsor
Alcon, a Novartis Company
Collaborator